The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Combination therapy based on nano codelivery for overcoming cancer drug resistance
Open accessAbstract
Multidrug resistance (MDR) has long been a major obstacle in the treatment of malignant tumors. Combination therapy provides a viable and promising strategy to overcome MDR. This article discusses the advantages of nano-based combination therapy and proposes a 3R delivery principle (right place, right time, and right dose) as a reference for development of cancer nanomedicine containing drug combinations. The article also reviews the strategies of nano-based codelivery, with emphasis on the techniques designed to overcome chemoresistance, enhance drug targeting delivery, and reduce immunosuppression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, to combat cancer’s multidrug resistance, smart nanoparticles transported synergistic drug combinations into cancer cells.335”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [335]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wang, H., Gao, Z. J., Liu, X., Agarwal, P., Zhao, S., Conroy, D. W., Ji, G., Yu, J., Jaroniec, C. P., Liu, Z., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02915-8 · Cited by 331
Self-citationRetractedCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,520
The Tumor Microenvironment Innately Modulates Cancer Progression
Hinshaw, D. C., & Shevde, L. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3962 · Cited by 3,270
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Metabolic reprogramming in macrophages and dendritic cells in innate immunity
Kelly, B., & O'Neill, L. A. (2015) · Cell Research · doi:10.1038/cr.2015.68 · Cited by 1,876
Flagged first, then by citations
Research works printed but not linked: 1
- Sharma, 2017, Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy, Cell, 168, 707
Cited by
Sorted by citations
Items 101–115 of 115
Nanocarrier-Based Drug Delivery in Cancer Therapy
Pandey, P., Patra, M. M., & Khandia, R. (2024) · Springer eBooks · doi:10.1007/978-981-97-8005-1_11 · Cited by 1
Rejili, M., Farahani, N., Alimohammadi, M., & Hushmandi, K. (2026) · Discover Oncology · doi:10.1007/s12672-026-05260-1 · Cited by 1
Kim, C. H., Lee, S. K., Choi, J. Y., Lyu, M. J., Jung, H. M., Goo, Y. T., Kang, M. J., & Choi, Y. W. (2022) · Research Square · doi:10.21203/rs.3.rs-1880173/v1 · Cited by 1
Ashoori, F., Verdom, B. H., Satari, M., & Abdolmaleki, P. (2021) · Research Square · doi:10.21203/rs.3.rs-138892/v1
Drug Resistance in Lung Cancer
Colarusso, C., Terlizzi, M., Pinto, A., & Sorrentino, R. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_62
Peng, T., & Huang, Y. (2025) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/csb-2025-5078
Self-citationNanocrystals Applications in Cancer Therapy
Mukherjee, S., Madamsetty, V. S., Reddy, R., Pradhan, L., Yenurkar, D., Manna, S., & Banerjee, D. (2025) · Synthesis lectures on biomedical engineering · doi:10.1007/978-3-032-04133-3_3
Nanotechnology for combating chemoresistance in peripheral cancers
DCruz, C. E. M., Dhiman, A., Karmakar, A., Shirodkar, R. K., & Kumar, L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33343-9.00005-3
Biodegradable polymeric nanofiber–mediated drug delivery approach for localized cancer chemotherapy
Rout, B., Maharana, S. K., Devaraj, Peddinti, V., & Jain, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27745-0.00010-7
Liposomes: Design, Development, Structure, Composition, Types and Related Techniques
Chu, C., Hua, C., & Geng, S. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674220-00019 · Cited by 1
Innovative Drug Delivery Systems: Pharmacological Approaches for Enhanced Therapeutic Outcomes
Rehman, H. F., Ikram, R., YAHYA, M., SIAL, H., Ali, A., NOOR, R., & Abbas, I. (2025) · doi:10.61748/apit.2025/04
Targeting methylation and acetylation in colon cancer
Gopathy, S., Lakshmanan, D., AROCKYASAMY, A. S., Srividya, S., & Bhavani, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27765-8.00006-0
Rafiya, K., Nadeem, M., Iqbal, M. A., Rizvi, M. M. A., Hasan, N., & Ahmad, F. J. (2026) · BioNanoScience · doi:10.1007/s12668-026-02531-7
Heiler, A. J., McClain, C. A., Lucas, S. N., He, G. Z., Finn, M. G., & Thomas, S. N. (2026) · Biomacromolecules · doi:10.1021/acs.biomac.5c02689
Mansour, S. T., & Mamdouh, W. (2026) · Cancer Nanotechnology · doi:10.1186/s12645-026-00412-y
Metadata
- Authors
- Wang, H., & Huang, Y.
- Affiliations
- Chinese Academy of Sciences (CN)
- Corresponding author
- Huang, Yongzhuo
- Venue
- Medicine in Drug Discovery
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 6
- Pages
- 100024
- ISSN
- 2590-0986 (ISSN-L)
- OpenAlex
- W3014110015
- Cited by
- 115
- References
- 112
- Citations by year
- 2026: 6 · 2025: 23 · 2024: 23 · 2023: 24 · 2022: 24 · 2021: 13 · 2020: 2
- FWCI
- 4.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Medicine in Drug Discovery (publishedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- multidrug resistance, combination therapy, cancer nanomedicine, chemoresistance, immunosuppression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
